Double blind trial of adjunctive valacyclovir in individuals with schizophrenia who are seropositive for cytomegalovirus

Faith B. Dickerson, Cassie R. Stallings, John J. Boronow, Andrea E. Origoni, Anne Sullens, Robert H. Yolken

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To investigate if adjunctive valacyclovir, an antiviral medication, reduces symptoms of persistent schizophrenia in individuals who are seropositive for cytomegalovirus (CMV). Method: N = 47 CMV seropositive schizophrenia outpatients were randomly assigned to receive valacyclovir 1 g twice daily (n = 24) or placebo (n = 23) for 16 weeks after a 2-week placebo run-in. Symptoms were assessed biweekly. Results: There was no significant difference in the change of positive, negative, general, or total PANSS symptoms between the valacyclovir vs. the placebo group. Conclusions: The study did not demonstrate benefit of adjunctive valacyclovir for schizophrenia individuals with persistent symptoms who are CMV seropositive.

Original languageEnglish (US)
Pages (from-to)147-149
Number of pages3
JournalSchizophrenia Research
Volume107
Issue number2-3
DOIs
StatePublished - Feb 2009

Keywords

  • Antiviral medication
  • Cytomegalovirus
  • Herpes virus
  • Schizophrenia
  • Valtrex

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Double blind trial of adjunctive valacyclovir in individuals with schizophrenia who are seropositive for cytomegalovirus'. Together they form a unique fingerprint.

Cite this